Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Nkarta stock | $24.35

Learn how to easily invest in Nkarta stock.

Nkarta, Inc is a biotechnology business based in the US. Nkarta shares (NKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Nkarta employs 107 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Nkarta

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NKTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Nkarta stock price (NASDAQ: NKTX)

Use our graph to track the performance of NKTX stocks over time.

Nkarta shares at a glance

Information last updated 2021-07-01.
Latest market close$24.35
52-week range$22.46 - $79.16
50-day moving average $26.43
200-day moving average $40.93
Wall St. target price$77.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.88

Buy Nkarta shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
M1 Finance
Stocks, ETFs
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Nkarta stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nkarta price performance over time

Historical closes compared with the close of $24.35 from 2021-05-28

1 week (2021-06-29) -17.96%
1 month (2021-06-02) -3.45%
3 months (2021-04-05) -27.36%
6 months (2021-01-05) -56.89%
1 year (2020-07-02) N/A
2 years (2019-07-02) N/A
3 years (2018-07-02) N/A
5 years (2016-07-02) N/A

Nkarta financials

Revenue TTM $385
Gross profit TTM $-36,220,000
Return on assets TTM -20.99%
Return on equity TTM -61.44%
Profit margin 0%
Book value N/A
Market capitalisation $1 billion

TTM: trailing 12 months

Shorting Nkarta shares

There are currently 2.0 million Nkarta shares held short by investors – that's known as Nkarta's "short interest". This figure is 7.1% down from 2.1 million last month.

There are a few different ways that this level of interest in shorting Nkarta shares can be evaluated.

Nkarta's "short interest ratio" (SIR)

Nkarta's "short interest ratio" (SIR) is the quantity of Nkarta shares currently shorted divided by the average quantity of Nkarta shares traded daily (recently around 207100.94537815). Nkarta's SIR currently stands at 9.52. In other words for every 100,000 Nkarta shares traded daily on the market, roughly 9520 shares are currently held short.

However Nkarta's short interest can also be evaluated against the total number of Nkarta shares, or, against the total number of tradable Nkarta shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nkarta's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Nkarta shares in existence, roughly 60 shares are currently held short) or 0.1428% of the tradable shares (for every 100,000 tradable Nkarta shares, roughly 143 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Nkarta.

Find out more about how you can short Nkarta stock.

Nkarta share dividends

We're not expecting Nkarta to pay a dividend over the next 12 months.

Nkarta overview

Nkarta, Inc. , a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was incorporated in 2015 and is based in South San Francisco, California. .

Frequently asked questions

What percentage of Nkarta is owned by insiders or institutions?
Currently 10.702% of Nkarta shares are held by insiders and 86.852% by institutions.
How many people work for Nkarta?
Latest data suggests 107 work at Nkarta.
When does the fiscal year end for Nkarta?
Nkarta's fiscal year ends in December.
Where is Nkarta based?
Nkarta's address is: 6000 Shoreline Court, South San Francisco, CA, United States, 94080
What is Nkarta's ISIN number?
Nkarta's international securities identification number is: US65487U1088

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site